Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases

For the preclinical study, colitis was induced in mice using 4% dextran sulfate sodium (DSS) in drinking water. Mice were treated with PALI-2108 at 20, 40, or 80 mg/kg BID, cyclosporine A (40 mg/kg), or apremilast (12.5 mg/kg). Clinical disease progression was monitored through changes in body weight, stool consistency, and fecal blood scores, with the Disease Activity Index (DAI) calculated to quantify disease severity. Colon biopsies were collected for analysis of PDE4B expression, expression of inflammat ...